As tumor regression was not detectable in the CT26/HER2 cell-challenged mice (Figure 1A), we speculated that CT26/HER2 cells might possess the capacity to resist the antitumor immunity that was induced by the CT26/HER2 cells. This evidence concerns the gene ERBB2 and neoplasm.